Drug Discovery & Pharmaceuticals

RSS

Accelerate Your Research: Dispen3D Harnesses the Power of 3D Models

Dispen3D is setting new standards in single-cell biology, enabling researchers to conduct high-precision experiments that drive advancements in drug discovery, personalized medicine, and regenerative therapies.

From SEED Biosciences 12 Jul 2024

Enzymatic RNA synthesis paves the way for sustainable therapeutics

While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and amyloidosis.

12 Jul 2024

Existing drug shows promise for treating common liver disease

The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects one in four people. The drug has long been marketed in Japan for another use: improving blood lipid levels in patients with hyperlipidaemia, a common condition in diabetics. Now, however, it could help address this serious liver disease, which still has no specific treatment.

11 Jul 2024

Click-like chemistry enables rapid development of LNPs for enhanced mRNA delivery

Imagine a scenario where a skilled hacker must upload critical software to update a central server and thwart a potentially lethal virus from wreaking havoc across a vast computer network.

10 Jul 2024

Newcells Biotech appoints Emile Shaffu as Director of Sales

Newcells Biotech, a leading drug discovery partner specializing in developing in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, today announced the appointment of Emile Shaffu as Director of Sales.

From Newcells Biotech 9 Jul 2024

Protein nanocages: A promising frontier in mRNA therapeutics

In recent years, messenger RNA (mRNA) has emerged as a promising avenue for accurate and potent therapeutic interventions. Unlike DNA drugs, mRNA can express genetic information without the risk of integrating into the host genome.

3 Jul 2024

Moffitt scientists develop breakthrough method for scalable synthesis of withanolides

Withanolides, a class of naturally occurring compounds found in plants, have long been a focus of cancer research due to their ability to inhibit cancer cell growth, induce cell death and prevent metastasis.

28 Jun 2024

ELRIG UK and The Protein Society Partner to advance protein sciences in drug discovery

Partners to host joint conference on ‘Protein Sciences in Drug Discovery’ in Cambridge, UK from 18–19 November 2024.

From ELRIG (UK) Ltd. 26 Jun 2024

New enzyme targets hold promise for cancer therapies

Researchers at Baylor College of Medicine and collaborating institutions have uncovered new potential therapeutic targets for cancer and new insights into existing cancer drug targets, expanding the breadth of possibilities for treating this disease. Using a comprehensive approach that included integrating proteomics, genomics and epigenomics data from 10 cancer types, the team identified protein and small protein or peptide targets in cancer tissues and validated many of them experimentally as promising candidates for therapeutic strategies. The study appeared in Cell.

25 Jun 2024

Advances in Diels-Alder synthesis of hydrocarbazole compounds using lanthanide catalysts

Hydrocarbazole is a crucial compound in organic chemistry, serving as a building block for various biologically active compounds, including pesticides like strychnine and anticancer drugs such as vinblastine and minovincine.

24 Jun 2024

Transforming drug discovery with AI

A new AI-powered program will allow researchers to level up their drug discovery efforts.

21 Jun 2024

Insilico Medicine leadership team shares insights on AI-powered healthcare innovation

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announces that the co-CEOs of the company – Alex Zhavoronkov, PhD, and Feng Ren, PhD – will be attending the 15th Annual Meeting of the New Champions, also known as Summer Davos hosted by the World Economic Forum, in Dalian, China, from 25 to 27 June 2024.

21 Jun 2024

Using deep learning to design synthetic soluble versions of cell membrane proteins

Many drug and antibody discovery pathways focus on intricately folded cell membrane proteins: when molecules of a drug candidate bind to these proteins, like a key going into a lock, they trigger chemical cascades that alter cellular behavior.

21 Jun 2024

Artificial variants of Withanolides act highly specifically against leukemia cells

Nightshade plants produce a diverse array of compounds with therapeutic potential. Researchers at CeMM have now identified an artificial variant inspired by the Withanolides group that acts highly specifically against leukemia cells.

21 Jun 2024

Novel AI tool poised to reshape virtual screening in early stage drug discovery

Australian researchers, led by Monash University, have invented a new artificial intelligence (AI) tool which is poised to reshape virtual screening in early stage drug discovery and enhance scientists’ ability to identify potential new medicines.

19 Jun 2024

CCDC leverages computing power of Intel and AWS for advancement in drug discovery

Thanks to the combined computing power of Amazon Web Services (AWS) and Intel, the CCDC announces that a potentially significant advancement in drug discovery has been achieved.

18 Jun 2024

Release of Unity 2.0: Order, track, and manage your compound collection through one platform

eMolecules has launched a new updated platform that enables medicinal chemists or compound managers to order, track, and manage their compound collection and commercial sources through a more intuitive and flexible system: Unity.

From eMolecules 13 Jun 2024

From Discovery Biology to ELRIG Chair: A Conversation with Melanie Leveridge

In this interview, we speak with Melanie Leveridge, Vice President of Discovery Biology at AstraZeneca and Chair of the Board for ELRIG UK, to discuss her extensive career in the pharmaceutical industry, her role in fostering scientific innovation, and her vision for ELRIG's future.

From ELRIG (UK) Ltd. 13 Jun 2024

Deep learning revives ancient peptides to battle antibiotic resistance

Researchers used deep learning to resurrect antibiotic peptides from extinct organisms, offering new solutions for combating antibiotic resistance.

12 Jun 2024

Researchers engineer water-soluble histidine kinase for enhanced antibiotic drug screens

A bacterial enzyme called histidine kinase is a promising target for new classes of antibiotics. However, it has been difficult to develop drugs that target this enzyme, because it is a "hydrophobic" protein that loses its structure once removed from its normal location in the cell membrane.

11 Jun 2024

Drug Discovery & Pharmaceuticals

Accelerate Your Research: Dispen3D Harnesses the Power of 3D Models

Enzymatic RNA synthesis paves the way for sustainable therapeutics

Existing drug shows promise for treating common liver disease

Click-like chemistry enables rapid development of LNPs for enhanced mRNA delivery

Newcells Biotech appoints Emile Shaffu as Director of Sales

Protein nanocages: A promising frontier in mRNA therapeutics

Moffitt scientists develop breakthrough method for scalable synthesis of withanolides

ELRIG UK and The Protein Society Partner to advance protein sciences in drug discovery

New enzyme targets hold promise for cancer therapies

Advances in Diels-Alder synthesis of hydrocarbazole compounds using lanthanide catalysts

Transforming drug discovery with AI

Insilico Medicine leadership team shares insights on AI-powered healthcare innovation

Using deep learning to design synthetic soluble versions of cell membrane proteins

Artificial variants of Withanolides act highly specifically against leukemia cells

Novel AI tool poised to reshape virtual screening in early stage drug discovery

CCDC leverages computing power of Intel and AWS for advancement in drug discovery

Release of Unity 2.0: Order, track, and manage your compound collection through one platform

From Discovery Biology to ELRIG Chair: A Conversation with Melanie Leveridge

Deep learning revives ancient peptides to battle antibiotic resistance

Researchers engineer water-soluble histidine kinase for enhanced antibiotic drug screens

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest Life Science News